Atomi Financial Group Inc. Acquires New Position in Natera, Inc. (NASDAQ:NTRA)

Atomi Financial Group Inc. acquired a new position in Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,836 shares of the medical research company’s stock, valued at approximately $291,000.

Several other large investors have also made changes to their positions in NTRA. Versant Capital Management Inc boosted its position in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares in the last quarter. Quarry LP grew its holdings in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares in the last quarter. Covestor Ltd boosted its holdings in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the last quarter. Finally, True Wealth Design LLC acquired a new stake in shares of Natera in the third quarter valued at approximately $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Natera news, Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the sale, the director now directly owns 19,386 shares of the company’s stock, valued at approximately $3,073,262.58. This represents a 10.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider John Fesko sold 669 shares of Natera stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total transaction of $106,772.40. Following the sale, the insider now directly owns 114,142 shares of the company’s stock, valued at approximately $18,217,063.20. This trade represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 243,546 shares of company stock worth $40,338,829. Corporate insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. JPMorgan Chase & Co. upped their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. The Goldman Sachs Group increased their price target on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Finally, Sanford C. Bernstein lifted their price target on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $162.94.

Natera Stock Performance

NASDAQ NTRA opened at $167.61 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a market cap of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. The stock has a 50-day moving average of $166.20 and a two-hundred day moving average of $136.43. Natera, Inc. has a 1-year low of $62.96 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the previous year, the business posted ($0.95) earnings per share. The business’s quarterly revenue was up 63.9% compared to the same quarter last year. As a group, analysts anticipate that Natera, Inc. will post -1.56 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.